JAMA Network
About The Study: In this study of patients with type 2 diabetes who had no prior eye disorders, patients prescribed semaglutide or tirzepatide had an increased risk of nonarteritic anterior ischemic optic neuropathy and other optic nerve disorders, although the overall risk was low. These findings highlight the need for close monitoring of these conditions.
/Public Release. This material from the originating organization/author(s) might be of the point-in-time nature, and edited for clarity, style and length. Mirage.News does not take institutional positions or sides, and all views, positions, and conclusions expressed herein are solely those of the author(s).View in full here.
